Premium
Efficacy of low‐dose cyclosporin A in psoriasis: results of dose‐finding studies
Author(s) -
TIMONEN P.,
FRIEND D.,
ABEYWICKRAMA K.,
LABURTE C.,
GRAFFENRIED B.,
FEUTREN G.
Publication year - 1990
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1990.tb02880.x
Subject(s) - medicine , clinical immunology , psoriasis , family medicine , clinical research , library science , dermatology , immunology , computer science , allergy
SUMMARY The efficacy of cyclosporin A (CyA) in severe psoriasis was analysed in 457 adult patients included in five European multicentre dose‐finding studies. Initial CyA doses were 1–25 mg/kg/day in 33 patients, 2.5–3 mg/kg/day in 285 and 5 mg/kg/day in 139. After 3 months of treatment, the reduction of the Psoriasis Area and Severity Index (PASI) score was 35 ± 6% with 1–25 mg/kg/day of CyA, 57 ± 2% with 2.5 mg or 3 mg/kg/day and 86 ± 2% with 5 mg/kg/day (P < 0.001). The rates of success, defined by a PASI score reduction ± 75% or a score ± 8, were 24%, 52% and 88%, respectively. There were no differences in age, initial severity or duration of psoriasis. The improvement was maintained for 9 months or more in the majority of patients receiving continuous CyA therapy.